Hydroxychloroquine sulfate
Hydroxychloroquine sulfate is a pharmaceutical drug with 21 clinical trials. Currently 1 active trials ongoing. Historical success rate of 40.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
8
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
30.8%
4 of 13 finished
69.2%
9 ended early
1
trials recruiting
21
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma
Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)
Acute Rhabdomyolysis and Muscle Pain Associated With Mutations in the LPIN1 Gene - A Retrospective Study Describing the Safety and Efficacy of Hydroxychloroquine Sulfate Given on a Compassionate Basis to Patients Suffering From Lipin-1 Deficiency
LY3214996 +/- HCQ in Pancreatic Cancer
Study on Optimization and Evaluation of Integrated Chinese and Western Medicine for pSS Glandular Damage
Clinical Trials (21)
Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma
Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)
Acute Rhabdomyolysis and Muscle Pain Associated With Mutations in the LPIN1 Gene - A Retrospective Study Describing the Safety and Efficacy of Hydroxychloroquine Sulfate Given on a Compassionate Basis to Patients Suffering From Lipin-1 Deficiency
LY3214996 +/- HCQ in Pancreatic Cancer
Study on Optimization and Evaluation of Integrated Chinese and Western Medicine for pSS Glandular Damage
Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19
Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19
Treatment for COVID-19 in High-Risk Adult Outpatients
Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19
Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals
Hydroxychloroquine for COVID-19
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)
Norwegian Coronavirus Disease 2019 Study
Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk
Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)
A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy
Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 21